Literature DB >> 10812222

Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies.

T Tims1, D J Briggs, R D Davis, S M Moore, Z Xiang, H C Ertl, Z F Fu.   

Abstract

Retired greyhound dogs, with low or absent antibody titers to rabies virus following previous vaccinations with commercially available vaccines, were immunized either subcutaneously or intramuscularly with a replication-defective recombinant adenovirus expressing the rabies virus glycoprotein termed Adrab.gp. Immunized animals developed high titers (geometric mean titers of 2630 and 5329) of viral neutralizing antibodies (VNA) against rabies virus by 10 days after vaccination. The antibody titers were even higher (geometric mean titers of 19349 and 122086) by 21 days after vaccination. The results indicate that the recombinant adenovirus expressing rabies virus glycoprotein is capable of inducing antibody immune responses in dogs and therefore may be developed as a rabies virus vaccine for dogs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812222     DOI: 10.1016/s0264-410x(00)00088-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing.

Authors:  Nia Tatsis; Shih-Wen Lin; Kimberly Harris-McCoy; David A Garber; Mark B Feinberg; Hildegund C J Ertl
Journal:  Virology       Date:  2007-06-27       Impact factor: 3.616

2.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs.

Authors:  James P McGettigan; Frederic David; Monica Dias Figueiredo; Jules Minke; Teshome Mebatsion; Matthias J Schnell
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

4.  Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Joseph P Balint; Stephanie Balcaitis; Brigitte Sanders-Beer; Frank R Jones
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

5.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

6.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

Authors:  Kimberly McCoy; Nia Tatsis; Birgit Korioth-Schmitz; Marcio O Lasaro; Scott E Hensley; Shih-Wen Lin; Yan Li; Wynetta Giles-Davis; Ann Cun; Dongming Zhou; Zhiquan Xiang; Norman L Letvin; Hildegund C J Ertl
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

9.  Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.

Authors:  Zhiquan Xiang; Guangping Gao; Arturo Reyes-Sandoval; Christopher J Cohen; Yan Li; Jeffrey M Bergelson; James M Wilson; Hildegund C J Ertl
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Novel vaccines to human rabies.

Authors:  Hildegund C J Ertl
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.